Apimeds Pharmaceuticals US, Inc

APUS · NYSE
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$1,781-$2,662-$402-$312
Dep. & Amort.$1$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$17-$2,605$344$176
Other Non-Cash$36$1,906$38$36
Operating Cash Flow-$1,726-$3,361-$20-$100
Investing Activities
PP&E Inv.-$23-$13$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$23-$13$0$0
Financing Activities
Debt Repay.$0$0$250$0
Stock Issued$0$11,953$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$94$17$77
Financing Cash Flow$0$11,859$267$77
Forex Effect$0$0$0$0
Net Chg. in Cash-$1,749$8,485$247-$23
Supplemental Information
Beg. Cash$8,735$250$3$27
End Cash$6,987$8,735$250$3
Free Cash Flow-$1,749-$3,374-$20-$100
Apimeds Pharmaceuticals US, Inc (APUS) Financial Statements & Key Stats | AlphaPilot